- Home
- AMST vs APVO Comparison
AMST vs APVO Comparison
Compare AMST & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMST
- APVO
- Stock Information
- Founded
- AMST 2017
- APVO 2016
- Country
- AMST United States
- APVO United States
- Employees
- AMST N/A
- APVO N/A
- Industry
- AMST Computer Software: Prepackaged Software
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- AMST Technology
- APVO Health Care
- Exchange
- AMST Nasdaq
- APVO Nasdaq
- Market Cap
- AMST 9.5M
- APVO 4.1M
- IPO Year
- AMST 2020
- APVO N/A
- Fundamental
- Price
- AMST $3.25
- APVO $3.00
- Analyst Decision
- AMST
- APVO Strong Buy
- Analyst Count
- AMST 0
- APVO 1
- Target Price
- AMST N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- AMST 104.6K
- APVO 6.7M
- Earning Date
- AMST 05-15-2025
- APVO 08-07-2025
- Dividend Yield
- AMST N/A
- APVO N/A
- EPS Growth
- AMST N/A
- APVO N/A
- EPS
- AMST N/A
- APVO N/A
- Revenue
- AMST $82,544.00
- APVO N/A
- Revenue This Year
- AMST N/A
- APVO N/A
- Revenue Next Year
- AMST N/A
- APVO N/A
- P/E Ratio
- AMST N/A
- APVO N/A
- Revenue Growth
- AMST N/A
- APVO N/A
- 52 Week Low
- AMST $2.00
- APVO $2.81
- 52 Week High
- AMST $6.27
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- AMST 59.77
- APVO 34.83
- Support Level
- AMST $3.13
- APVO $2.89
- Resistance Level
- AMST $3.77
- APVO $3.20
- Average True Range (ATR)
- AMST 0.24
- APVO 0.27
- MACD
- AMST 0.07
- APVO 0.24
- Stochastic Oscillator
- AMST 58.60
- APVO 10.63
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.